Amsterdam

• A clinical study of new treatments given with enfortumab vedotin and pembrolizumab in people with urothelial cancer (MK-3475-04D) Recruiting
  2025-522253-19-00 9 2026-02-11 Urothelial carcinoma
• NON-IV: Neo-adjuvant peritumOral immuNotherapy In Vulvar cancer Recruiting
  2025-520712-34-00 3 2026-02-04 Vulvar Cancer
• A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific … Recruiting
  2025-522767-15-00 5 2026-01-27 Acute Myeloid Leukemia
• Study for frail patients with newly diagnosed multiple myeloma treated with Daratumumab in combination with Teclistamab and Talquetamab. Recruiting
  2024-520433-76-00 4 2026-01-08 Newly Diagnosed Multiple Myeloma
• A study to assess efficacy and safety of empasiprubart versus IVIg in adults with CIDP ("emvigorate") Recruiting
  2024-520097-36-00 5 2026-01-07 Chronic inflammatory demyelinating polyneuropathy (CIDP)
• Study to investigate lifileucel regimen plus pembrolizumab compared with pembrolizumab alone in participants with untreated, advanced melano … Recruiting
  2022-503140-41-00 5 2025-12-19 Melanoma
• A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and be … Recruiting
  2024-510778-26-00 4 2025-12-19 Metastatic Non-Small-Cell Lung Cancer
• HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanc … Recruiting
  2024-516253-49-01 4 2025-12-12 advanced/metastatic HER2-positive breast carcinoma
• Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-riskrectal cancer. Recruiting
  2024-517700-12-00 5 2025-12-10 Rectal cancer
• A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Partic … Recruiting
  2024-519157-10-00 3 2025-11-24 Systemic Lupus Erythematosus
• Phase 3 trial of eRapa in patients with familial adenomatous polyposis (FAP) Recruiting
  2025-522946-37-00 5 2025-11-24 Familial adenomatous polyposis (FAP)
• A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Safety of ELGN-2112 in Populations … Recruiting
  2024-517102-29-00 5 2025-11-19 Intestinal Malabsorption
• A first-in-human study to learn how safe BAY 3713372 is and how it works in participants with MTAP-deleted solid tumors Recruiting
  2025-520623-24-00 7 2025-11-19 MTAP-deleted Solid Tumors
• The IPa-Gastric trial: Comparing Intraperitoneal Paclitaxel and Systemic Therapy versus Systemic Therapy alone in Gastric Cancer Patients wi … Recruiting
  2024-514879-17-00 5 2025-11-05 Gastric cancer
• EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial-1) Recruiting
  2025-521315-39-00 1 2025-11-05 Axial spondyloarthritis
• T3-4-Hypo trial Recruiting
  2024-513883-24-00 5 2025-11-02 Hypothyroidism Triiodothyronine Quality of Life Persistant complaints
• Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting
  2024-519423-24-00 5 2025-10-07 Major Depressive Disorder
• A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o … Recruiting
  2023-508056-19-00 5 2025-10-02 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting
  2024-518296-56-00 5 2025-09-29 Crohn’s Disease
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe … Recruiting
  2024-520209-38-00 5 2025-09-19 Obesity or Overweight
• Open-label Study of ELA026 in Participants with sHLH (short title) Recruiting
  2025-520624-25-00 10 2025-09-19 Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
• Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 Recruiting
  2024-518144-20-00 7 2025-09-03 Primary Hyperoxaluria Type 1 (PH1)
• Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting
  2024-520107-12-00 5 2025-09-03 Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
• The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting
  2024-518589-29-00 5 2025-08-21 Bronchiectasis

Showing 121–144 of 1,112 trials